Reata Pharmaceuticals Competitors and Similar CompaniesClear all
Reata Pharmaceuticals's competitors and similar companies include Apellis Pharmaceuticals, Ionis Pharmaceuticals and Kadmon.
 Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. |  Apellis Pharmaceuticals Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds. |  Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. |  Kadmon Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C. | |
Founding Date | Founding Date 2002 | Founding Date 2009 | Founding Date 1989 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Waltham, US HQ Kew East, AU München, DE Zug, CH San Francisco, US Watertown, US | Locations New York, US HQ Cambridge, US South Brunswick Township, US Warrendale, US | |
Employees | Employees 3217% decrease | Employees 7028% decrease | Employees 1,40231% increase | Employees 44 |
Valuation ($) | Valuation ($) 6.6 b | Valuation ($) 3.3 b | Valuation ($) 6.3 b | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) $1b (FY, 2025) | Revenue (est.) $943.7m (FY, 2025) | Revenue (est.) $8.3m (FY, 2020) |
Net income | Net income ($311.9m) (FY, 2022) | Net income $22.4m (FY, 2025) | Net income ($381.4m) (FY, 2025) | Net income ($108.9m) (FY, 2020) |
Operating ⚠ | ||||
Phase I Trials Products | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2023) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products 18 (FY, 2024) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products 17 (FY, 2024) | Phase III Trials Products N/A |
Funding | ||||
Total funding raised | Total funding raised $ 468.9m | Total funding raised $ 88m | Total funding raised N/A | Total funding raised $ 21.3m |
For sources of this data, please see the company profile
View Company Profiles
Apellis Pharmaceuticals
HQ
Waltham, US
Employees
702↓ 8% decrease
Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds.
View companyIonis Pharmaceuticals
HQ
Carlsbad, US
Employees
1,402↑ 31% increase
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
View companyKadmon
HQ
New York, US
Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C.
View company